pharma · Severe, Refractory Systemic Lupus Erythematosus · Refractory Progressive Multiple Sclerosis · AUTL
Autolus
Autolus GmbH
Tubulis is a pharma organization headquartered in Munich, DE. It trades on NYSE under ticker AUTL. Primary therapeutic focus areas include Severe, Refractory Systemic Lupus Erythematosus, Refractory Progressive Multiple
Munich, Bayern 81377, DE HQ
117 Employees
Public company Type
AUTL · NYSE Ticker
Company details
- Status
- Public
- HQ
- Munich, Bayern 81377, DE
- Employees
- 117
- Programs
- 16
- Drugs
- 17
- Patents
- 49
Obecabtagene autoleucel
Phase 2 · small molecule · Acute Lymphocytic Leukemia (ALL)
Obecabtagene autoleucel for Acute Lymphocytic Leukemia (ALL) is a Phase 2 program (small_molecule) at Autolus GmbH with 1 ClinicalTrials.gov record(s).
Internal code 2025-0580
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Autolus GmbH
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Acute Lymphocytic Leukemia (ALL)
- Status
- active
- Trials
- 1